new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 receptor agonists | How

Ongoing trials with incretin-based therapies that investigate potential renoprotective mechanisms

GLP-1RAs have been shown to reduce the levels of systemic inflammatory markers

& Suzuki, A

Scouted selects products independently

Based on the strength of the clinical data, we expect Wegovy to be added to formularies with utilization management restrictions for prior authorization to prevent off-label use, shorter initial approval periods (e.g., six months approved initially) to ensure efficacy, and quantity limits to reduce stockpiling and waste

The GLP-1R interacts with structurally related peptide hormone ligands, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), parathyroid hormone, etc